

Cell Reports, Volume 33

Supplemental Information

TET2-Loss-of-Function-Driven Clonal

Hematopoiesis Exacerbates Experimental


Insulin Resistance in Aging and Obesity

José J. Fuster, María A. Zuriaga, Virginia Zorita, Susan MacLauchlan, Maya N. Polackal, Vanesa Viana-Huete, Alba Ferrer-Pérez, Nuria Matesanz, Andrea Herrero-Cervera, Soichi Sano, Matthew A. Cooper, Herminia González-Navarro, and Kenneth Walsh


SUPPLEMENTAL MATERIAL

Gene	Forward Primer	Reverse Primer
<i>36b4</i>	GCTCCAAGCAGATGCAGCA	CCGGATGTGAGGCAGCAG
<i>β-actin</i>	GGCTGTATTCCCCTCCATCG	CCAGTTGGTAACAATGCCATGT
<i>Tet2 (exons 8-9)</i>	AACCTGGCTACTGTCATTGCTC	ATGTTCTGCTGGTCTCTGTGGGAA
<i>Il1b</i>	TGACAGTGATGAGAATGACCT	TTGGAAGCAGCCCTTCATCT
<i>Il6</i>	GCTACCAAAGTGGATATAATCA	CCAGGTAGCTATGGTACTCCAGAA
<i>Il1a</i>	GCACCTTACACCTACCAGAGT	AAACTTCTGCCTGACGAGCTT
<i>Tnf</i>	CGGAGTCCGGGCAGG	GCTGGGTAGAGAATGGATGAA
<i>Ifng</i>	ACAGCAAGGCGAAAAAGGATG	TGGTGGACCACTCGGATGA
<i>Ccl2</i>	CAGCCAGATGCAGTTAACGC	GCCTACTCATTGGGATCATCTTG
<i>Cxcl1</i>	CCGAAGTCATAGCCACACTCAA	CAAGGGAGCTTCAGGGTCAA
<i>Cxcl2</i>	TGACTTCAAGAACATCCAGAGC	CTTGAGAGTGGCTATGACTTCTGTCT
<i>Cxcl5</i>	GCC GCT GGC ATT TCT GTT	GGG CAG CTT CAG CTA GAT GCT
<i>Ccl5</i>	CAGCAGCAAGTGCTCCAATC	CACACACTTGGCGTTTCCTT
<i>Emr1</i>	CTTTGGCTATGGGCTTCCAGTC	GCAAGGAGGACAGAGTTTATCGTG
<i>Cd68</i>	TTC TCC AGC TGT TCA CCT	GTT GCA AGA GAA ACA TGG CCC
<i>Cd11c</i>	ATG GAG CCT CAA GAC AGG	GGA TCT GGG ATG CTG AAA TC
<i>Selp</i>	CATCTGGTTCAGTGCTTTGATC	ACCCGTGAGTTATTCCATGAGT
<i>Sele</i>	ATGCCTCGCGCTTTCTCTC	GTAGTCCCGCTGACAGTATGC
<i>Icam1</i>	GTGATGCTCAGGTATCCATCCA	CACAGTTCTCAAAGCACAGCG
<i>Vcam</i>	TAGAGTGCAAGGAGTTCGGG	CCGGCATATACGAGTGTGAA
<i>Irs1</i>	CGATGGCTTCTCAGACGTG	CAGCCCGCTTGTTGATGTTG
<i>Irs2</i>	CTGCGTCCTCTCCCAAAGTG	GGGGTCATGGGCATGTAGC


Supplemental Table (related to STAR Methods). Oligonucleotides used as primers in qPCR assays.



Supplemental Figure S1 (related to Fig.1). *Tet2*^{-/-} (KO) or *+/+* (WT) CD45.1-CD45.2+ BM cells were delivered via adoptive transfer to non-conditioned 10 week-old CD45.1/CD45.2- recipient mice, which were then monitored until the age of 84 weeks (~1.6 years). n=9 WT, 6 KO mice. **A.** % of CD45.2+ cells within Lineage⁻ Sca1⁺ Kit⁺ (LSK) HSPC populations in bone marrow. **B.** % of CD45.2+ cells within various blood cell populations, evaluated by flow cytometry at various time points (Cla: classical; Pat: patrolling monocytes). **C.** % of B-lymphoid (CD115⁻, Ly6G⁻, CD3-B220⁺), T-lymphoid (CD115⁻, Ly6G⁻, B220⁻ CD3⁺) and myeloid (CD115⁺ or Ly6G⁺) cells in CD45.2+ WBC populations at 82 weeks of age. **D.** Absolute counts of white blood cells (WBCs) and specific blood cell lineages at 82 weeks of age. **E.** Survival curves (initial sample size n=11 mice per BM genotype), compared using a Cox Mantel log-rank test. **F.** Body weight. **G.** % body fat and lean mass, assessed by magnetic resonance imaging. **H.** eWAT and liver weight. **I.** Western Blot analysis of Akt Ser473 phosphorylation in liver in *ad lib* fed mice. A representative blot is shown.



Supplemental Figure S2 (related to Fig.2). Competitive BMTs were used to generate mice carrying 10% *Tet2*^{-/-} (10% KO BMT) or *+/+* (10% WT BMT) hematopoietic cells, which were then fed HF/HS diet for 14 weeks. **A.** Summary of the BMT approach and the timeline of BMT and hematological and metabolic studies used to investigate the effects of TET2 loss of function-driven clonal hematopoiesis in obese mice. **B.** Absolute counts of WBCs and different blood cell lineages after 12 weeks of HF/HS diet feeding (17 weeks post-BMT, n=15 mice per BM genotype) (Cla: classical; Pat: patrolling monocytes). **C.** % of lymphoid (CD115⁻, Ly6G⁻ and B220⁺ or CD3⁺) and myeloid (CD115⁺ or Ly6G⁺) cells in CD45.2⁺ WBC populations (n=15 mice per BM genotype). **D.** eWAT, inguinal WAT (iWAT) and liver weight (n=11 per BM genotype). **E.** Western Blot analysis of insulin-induced Akt Ser473 phosphorylation in liver (n= 4 mice per BM genotype). **F.** % CD45.2⁺ cells within F4/80⁺ macrophage populations in matched eWAT, iWAT and liver samples (n=5 mice per BM genotype). **G, H.** qPCR analysis of transcript levels of several pro-inflammatory cytokines and chemokines in eWAT (G) and liver (H) (n=11 per BM genotype). **I.** ELISA analysis of IL-1β protein levels in iWAT and liver (n=11 per BM genotype).



Supplemental Figure S3 (related to Figs-1-3). A-C. HF/HS-diet fed 10% WT BMT and 10% KO BMT mice received a continuous infusion of MCC950 or phosphate buffered saline vehicle via subcutaneous osmotic pumps. (A) Timeline of BM transplantation, MCC950 treatment, HF/HS diet feeding and hematological and metabolic studies. (B) Body weight. (C) Percentage of CD45.2+ cells within WBCs and main blood cell lineages in 10% KO BMT mice after 17 weeks on HF/HS diet (21 weeks post-BMT), measured by flow cytometry (n=7 mice per treatment, MCC950 or PBS vehicle). **D, E.** qPCR analysis of transcript levels of endothelial adhesion molecules (D) and transcripts expressed at high levels in macrophages (E) in eWAT of obese 10% KO BMT and 10% WT BMT mice (n=11 per experimental group). **F, G.** Flow cytometry analysis of absolute numbers of F4/80+ macrophages and CD3+ T cells in eWAT of aged mice after adoptive transfer (F, n=9 WT, 6 KO) or obese mice after competitive BMT (G, n=7 10% WT BMT, n=6 10% KO BMT) mice. **H, I.** qPCR analysis of *Irs1* and *Irs2* transcript levels (H) and Spearman analysis of the correlation between *Irs1* and *Il1b* transcript levels (I) in eWAT of obese

10% KO BMT and 10% WT BMT mice (n=11 per BM genotype). **J, K.** qPCR analysis of *Irs1* and *Irs2* transcript levels (J) and Spearman analysis of the correlation between *Irs1* and *I1b* transcript levels (K) in eWAT of MCC950-treated 10% WT BMT mice and 10% KO BMT mice after 18 weeks on HF/HS diet (n=7 per BM genotype). In I and K, left panels show the combined analysis of all mice in each experiment; central and right panels show the analysis of each BM genotype separately. **L, M.** Cultured 3T3-L1 adipocytes were treated with conditioned medium (CM) from LPS/IFN γ -primed, ceramide-treated peritoneal macrophages (isolated from *Tet2*^{-/-} mice and WT controls) in the presence of an IL-1 β -neutralizing IgG or a control IgG. Adipocyte *Irs1* transcript expression was evaluated by qPCR (L, n=6 different conditioned media per genotype). Insulin-induced glucose uptake was assessed by a bioluminescent enzymatic method (M, n=3 different conditioned media per genotype; ***p=0.0002 by 2-way ANOVA with Sidak's multiple comparisons test). Data are shown relative to WT CM/control IgG-treated samples.